Fig. 5 | Nature Communications

Fig. 5

From: Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

Fig. 5

Anticancer synergy between LCL161 and VSVΔM51 is dose schedule dependent. a Overall survival of EMT6 tumor-bearing mice treated with LCL161 ± VSVΔM51 at different dosing schedules (duplicate experiments; log-rank test). b Cytokines within blood taken from EMT6 tumor-bearing mice treated with VSVΔM51 for 24 h, after 72 h pretreatment with LCL161 (or vehicle), measured by Luminex (single experiment; mean ± SD; t-test). c Concentration of type I IFN within EMT6 cell culture media 24 h after VSVΔM51±LCL161 pretreatment for 2 h, measured by ELISA (n = 3 biological replicates per experiment; duplicate experiments; mean ± SD). d Infectious VSVΔM51 particles isolated from tumor, TdLN, and spleen of EMT6 tumor-bearing mice 12 h after VSVΔM51 treatment ± LCL161 pretreatment for 72 h, measured by plaque assay (spleen, duplicate experiments; tumor and TdLN, single experiment; mean ± SD; t-test)

Back to article page